Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
This study has been terminated.
(Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.)
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
First received: September 19, 2012
Last updated: March 21, 2014
Last verified: March 2014
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793
Primary Outcome Measures:
- Adverse Events [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study
- Laboratory Data [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Assessments include hematology, clinical chemistry, urinalysis and urine drug/alcohol screens
- Vital Signs [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Assessments include pulse, blood pressure and oral body temperature
- Physical examinations [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
An examination of bodily functions and physical condition
- Brief Neurological examination [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Assessments include cranial nerves, motor and sensory system, reflexes, coordination, gait and station
- Brief Psychiatric assessments [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Assessments include mood, anxiety, psychosis or delusions, agitation, homicidal thoughts or behaviors
- Columbia-Suicide Severity Rating Scale [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
The scale is designed to assess suicidal behavior and ideation
- Cornell Scale for Depression in Dementia [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Assesses the signs and symptoms of major depression in patients with dementia
- Electrocardiogram [ Time Frame: Assessments up through 28 weeks ] [ Designated as safety issue: Yes ]
Measurements include heart rate, RR interval, PR interval, QRS duration and QT intervals
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2014 (Final data collection date for primary outcome measure)
ABT-126 Open-label dose
See arm description
This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study M11-793. Up to 420 subjects may participate at approximately 40 sites in seven countries.
|Ages Eligible for Study:
||55 Years to 90 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.
- The subject was randomized into Study M11-793 and completed dosing through Week 24 in that study.
- With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG.
- If male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study drug. However, if the male subject's partner has been postmenopausal for at least two years or is surgically sterile, then use of a barrier method of birth control is not required.
- The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.
- The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures.
- The subject experienced an adverse event or abnormal finding in physical examination, vital signs, laboratory profile and/or ECG measurements in Study M11-793 that indicates the subject could become medically unstable during the current study.
- The subject is currently taking or is expected to be prescribed any excluded medications without the approval of Abbott medical monitor.
- The subject was noncompliant with donepezil or rivastigmine during Study M11-793 or is expected to discontinue these medications prior to conclusion of this study.
- The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
- The subject is currently enrolled in, or plans to participate in, another experimental study during the course of this trial.
- The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in this study.
- For any other reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01690195
AbbVie (prior sponsor, Abbott)
||Laura Gault, MD
No publications provided
||AbbVie ( AbbVie (prior sponsor, Abbott) )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 19, 2012
||March 21, 2014
||United States: Food and Drug Administration
South Africa: Medicines Control Council
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Canada: Health Canada
France: Afssaps - Agence francaise de securite sanitaire des produits de sante (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Greece: National Organization of Medicines
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Nervous System Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs